The economic proposition of disease-modifying therapies represents a fundamental shift from the traditional cost-accumulation model of chronic kidney disease management to an investment model ...

Early diagnosis and intervention create a return on investment model where up-front costs for screening, diagnosis, and early treatment yield substantial downstream cost savings while ...

In the clinical development of NKX019 for autoimmune diseases, the Ntrust-1 trial of NKX019 for lupus nephritis (LN) expanded to include patients with primary membranous nephropathy (pMN).

Biogen), a first-line therapy for a patient with membranous nephropathy. The process was held up when initial communication from the carrier indicated prior authorization was required and then ...

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last ...

The drug is also in mid-stage clinical trials for primary membranous nephropathy (PMN) and antibody-mediated transplant rejection and is in phase 1 for lupus nephritis. According to the American ...

which along with PNH and IgAN include atypical haemolytic uraemic syndrome (aHUS), C3 glomerulopathy (C3G), and idiopathic membranous nephropathy (IMN). It still has a long way to go to reach that ...

Nephrology is specialty of medicine concerned with kidney physiology, kidney disease, the treatment of kidney problems and renal replacement therapy. Systemic conditions that affect the kidneys (e ...